# FDA Approves Ibrance Plus Trastuzumab for HR+/HER2+ Metastatic Breast Cancer Maintenance

> fda · REPORTED · 2026-06-26

On June 26, 2026, the FDA approved palbociclib (Ibrance) combined with trastuzumab, with or without pertuzumab, plus endocrine therapy as ongoing maintenance treatment for adults with hormone receptor-positive, HER2-positive locally advanced or metastatic breast cancer whose disease is controlled after induction therapy. This expands the use of the established CDK4/6 inhibitor into the HER2-positive breast cancer setting.

About Pfizer (Ibrance/Palbociclib): Pfizer's Ibrance (palbociclib) is a CDK4/6 inhibitor approved for hormone receptor-positive breast cancer; this new indication targets the HR+/HER2+ metastatic population as maintenance therapy.

- Company: Pfizer (Ibrance/Palbociclib)
- Sector: oncology
- Primary source: https://www.webmd.com/drugs/updates/default.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.